Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS‐HF trial-Reference-Cited by-同舟云学术

Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS‐HF trial

Published:2019-02-15 Issue:3 Volume:21 Page:345-351
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Ferreira João Pedro¹²,Abreu Paula³,McMurray John J.V.⁴,van Veldhuisen Dirk J.⁵,Swedberg Karl⁶,Pocock Stuart J.⁷,Vincent John³,Lins Katharina³,Rossignol Patrick¹,Pitt Bertram⁸,Zannad Faiez¹

Affiliation:

1. National Institute of Health and Medical Research (INSERM), Center for Clinical Multidisciplinary Research 1433, INSERM U1116, University of Lorraine, Regional University Hospital of Nancy, French Clinical Research Infrastructure Network (F‐CRIN) Investigation Network Initiative‐Cardiovascular and Renal Clinical Trialists (INI‐CRCT) Nancy France

2. Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine, Cardiovascular Research and Development UnitUniversity of Porto Porto Portugal

3. Pfizer Inc. New York NY USA

4. BHF Cardiovascular Research Centre, University of Glasgow Glasgow UK

5. Department of CardiologyUniversity Medical Center Groningen, University of Groningen Groningen The Netherlands

6. Department of Molecular and Clinical MedicineUniversity of Gothenburg Gothenburg Sweden

7. Department of Medical Statistics, London School of Hygiene and Tropical Medicine London UK

8. Department of MedicineUniversity of Michigan School of Medicine Ann Arbor MI USA

Funder

Pfizer

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.1400

Reference15 articles.

1. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

2. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

3. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry

5. Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of patients with heart failure and chronic kidney disease;Heart Failure Reviews;2024-07-29

2. Analysis of eplerenone in the FDA adverse event reporting system (FAERS) database: a focus on overall patient population and gender-specific subgroups;Frontiers in Pharmacology;2024-07-17

3. Generalizable Approach to Quantifying Guideline-Directed Medical Therapy;Circulation: Heart Failure;2024-05

4. What to do with foundation therapies for heart failure for patients with end-stage kidney disease on haemodialysis;British Journal of Hospital Medicine;2024-04-02

5. When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases;Nephrology Dialysis Transplantation;2024-01-08